Figure 3: Proportion of patients with sustained virologic response at weeks 48, 96 and 144, by TLOVR. NVP IR, nevirapine immediate release; NVP XR, nevirapine extended release; SVR, sustained virologic response; TLOVR, time to loss of virologic response.